Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Okyo Pharma Limited LSE:OKYO London Ordinary Share GG00BD3FV870 ORD NPV
  Price Change % Change Share Price Shares Traded Last Trade
  -0.50 -5.71% 8.25 656,355 16:06:46
Bid Price Offer Price High Price Low Price Open Price
8.00 8.50 8.75 8.25 8.75
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Mining -3.76 -0.01 52
Last Trade Time Trade Type Trade Size Trade Price Currency
16:20:02 O 250,000 8.25 GBX

Okyo Pharma (OKYO) Latest News

More Okyo Pharma News
Okyo Pharma Investors    Okyo Pharma Takeover Rumours

Okyo Pharma (OKYO) Discussions and Chat

Okyo Pharma Forums and Chat

Date Time Title Posts
25/2/202115:54OKYO Pharma PLC519
17/4/201904:44(OKYO) OKYO Pharma Says Data Shows Potential Of Its Dry Eye Treatment6
17/4/201904:44OKYO PHARMA (OKYO)14

Add a New Thread

Okyo Pharma (OKYO) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-02-25 18:06:038.25250,00020,625.00O
2021-02-25 17:16:258.00100,0008,000.00O
2021-02-25 16:20:048.5020,0001,700.00O
2021-02-25 16:05:288.3017,7171,470.51O
2021-02-25 15:27:398.302,167179.86O
View all Okyo Pharma trades in real-time

Okyo Pharma (OKYO) Top Chat Posts

DateSubject
25/2/2021
08:20
Okyo Pharma Daily Update: Okyo Pharma Limited is listed in the Mining sector of the London Stock Exchange with ticker OKYO. The last closing price for Okyo Pharma was 8.75p.
Okyo Pharma Limited has a 4 week average price of 8.25p and a 12 week average price of 6.95p.
The 1 year high share price is 18.75p while the 1 year low share price is currently 0.75p.
There are currently 636,297,049 shares in issue and the average daily traded volume is 552,438 shares. The market capitalisation of Okyo Pharma Limited is £52,494,506.54.
21/1/2021
08:48
wd1010: Price target next few months? I've been holding this for many months as can see huge potential. Current pipeline...First is is the potential treatment for dry eye conditions, known as OK-113. Based on pre-clinical tests, the company believes its candidate could prove superior to the current leading dry-eye product in the market, Allergan's Restatis, which generates annual sales of US$1.2bn.A second asset on OKYO's books is a potential non-opioid pain relief product. This again is a huge market. Third is the latest development "OKYO announces filing of a patent application covering the use of Chemerin and associated analogues to treat "cytokine storm" associated with COVID-19 and ARDS
13/1/2021
10:54
chris2020: New betaville article out on Okyo, yesterday.
11/10/2020
14:22
invester2010: note - teh dry eye market is multi-bllion dollar and OKYO has drug that meets the critiera for FDA appproval - hence big names on baord now.
11/10/2020
14:17
invester2010: Now OKYO is duel listing Nadaq and expect FDA sumbmission of the their eye drug very soon - that could be next news pending - which will be send the s soaring over 30p - as this market is multi-billion dollar and OKYO is right at the center. we will have great week here. imho.
18/9/2020
09:10
dodobird25: Volsung. You are evidently a committed OKYO investor. I also believe that the company has growth potential, and I intend to hold, through thick and thin, until the share price approaches double the current value, whenever that happens. Only then will I consider my position. My current holding is 200,000 shares @ approx. 11.1p ave. I have researched the company as fully as I am able, but from my experiences of other companies, I realise that there are investors out there with more detailed informatio than I am able to access. Should you have any information or insights, that you are willing to share, I would appreciate your input. Regards, and best wishes with your investments.
18/9/2020
07:45
volsung: You’re a lovely piece of work aren’t you p5? Sad when other people’s losses are your joy in life. The share price will improve but your sad life probably won’t
17/9/2020
14:55
dodobird25: Thank you for your reply. I am in total agreement, and I too should have sold when the OKYO share price was listed at around 18p. This has proven to be the case with other pharmaceuticals recently (TILS, SNG to mention two). No more FOMO for me - I have proven it to be a loser's game in the main part. From now on, I shall be selling, when a healthy profit has been achieved, and perhaps buying back if there is a significant pullback. I wish you well with your future investments. Your prediction regarding OKYO, when at its recent peak, has been proven to be correct. We should have a clearer indication as to where this share price is heading next week. I see nothing untoward in my research, but several companies, whose retail shareholders were anticipating significant growth following results, have come unstuck recently.
06/8/2020
14:06
spurs90: Jim Mellon has just dumped his entire stake in tiddler Okyo Pharma, which is developing therapies for inflammatory eye diseases and chronic pain management. Below is a link to the announcement that shows he went down from owning just over 4pc to almost 0. Https://www.investegate.co.uk/okyo-pharma-limited--okyo-/rns/holding-s--in-company/202008060700092951V/ Now, that does seem a strange move by Mellon - a 'billionaire' investor that is said to be friends with Brexit leader Aaron Banks - given Okyo shares have been surging in recent weeks to almost 17p. Watching...
28/7/2020
09:06
spurs90: OKYO Pharma Limited ("OKYO" or the "Company") Issue of convertible loan notes to raise £3,500,000 OKYO, the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that it has raised £3,500,000 through the issue of convertible loan notes ("CLNs"). The proceeds of the CLNs will be used for working capital purposes as detailed below. The CLNs carry an interest rate of 2.15% compounding and have maximum term of 4 years. The CLNs convert into ordinary shares at a price of 8.5p per share. Conversion will be subject to shareholder approval and no conversions may take place prior to 28 February 2021. The CLNs were placed with a small number of private investors. OKYO intends to use the net proceeds received from the CLNs, to further the development of its clinical pipeline. The person who arranged for the release of this announcement on behalf of the Company was Keeren Shah, Chief Financial Officer of OKYO.
24/7/2020
13:02
cumnor: Well, well, near 20 times jump in share price from placing price on no news that could remotely account for the rise-normally a company would come out with a 'we know no reason,,,,,' or 'if the directors have inside info relating to the rise it would of course, we presume, have been released if it is affecting the share price. But who knows? Big connections here with TILs-are its shareholders in for a reward, or a surprise re StemPrinter? Looking forward to see how the demerger transpires. imo
Okyo Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
OKYO
Okyo Pharm..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210226 04:20:38